With lead hepatitis C virus (HCV) candidate simeprevir (TMC435) nearing the finish line and two nucleotide (nuc) polymerase inhibitor candidates for HCV in its pipeline, Medivir AB pulled the plug on its NS5A inhibitor program, citing lack of market demand, difficulty meeting its development timetable and the desire to reallocate in-house resources. Read More
LONDON – In the past year the lure of gene silencing as a route to address disease has prompted a revival in the field. But it remains the case that the difficulties of delivering RNA-based drugs continue to slow the pace of development and limit their use to the liver or tumor tissues, or to tissues where local administration is possible. Read More
Shares in Immunicum AB surged more than 40 percent Monday on promising signals from a Phase I/II trial of its kidney cancer vaccine, Intuvax. Read More
LONDON – Glaxosmithkline plc (GSK) has put further flesh on its ambition to become a leader in electroceuticals – in which nanoscale devices will be used to modulate the body's neural circuits – with the announcement of a $50 million venture capital fund to back pioneers in the field. Read More
SHANGHAI – Highlighting increasing public concern over drug, device and food safety in China, a crackdown on illegal pharmaceutical advertising has led to a dramatic increase in the number of reported cases. Read More
• Prima Biomed Ltd., of Sydney, Australia, said the Korean Ministry of Food and Drug Safety granted approval to begin the Phase II/III CANcer VAccine Study (CANVAS) of CVac at several sites. The company expects the sites in Korea – the first in Asia – to begin recruiting in several weeks. Read More